Skip to main content

Advertisement

Table 1 Study characteristics

From: Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis

study No. of patients Gender M/F Age (< 70/≥70) Smoking status (C or F /N) Treatment Detecting Items for Drug-Resistance Mechanism
Uramoto H et al. [10] 11 3/8 7/4 2/9 gefitinib T790 M, KRAS,PTEN MET amp, HGF status
Kuiper JL et al. [11] 66 14/52 NA 30/33a erlotinib gefitinib T790 M, SCLC, KRAS
Sun JM et al. [12] 70 18/52 NA 14/56 erlotinib gefitinib T790 M
Li W et al. [13] 54 29/25 49/5 7/47 erlotinib gefitinib Icotinib T790 M
Sequist LV et al. [14] 37 15/22 31/6 NA erlotinib gefitinib T790 M, MET amp, SCLC, PIK3CA, EMT
Kosaka T et al. [15] 14 4/10 NA 6/8 Gefitinib T790 M, KRAS
Oxnard GR et al. [16] 93 33/60 NA 32/61 erlotinib gefitinib T790 M, MET amp, HER2
Hata A et al. [17] 78 24/54 51/27 24/54 erlotinib gefitinib T790 M
Chen HJ et al. [18] 29 18/11 27/2 6/23 erlotinib gefitinib T790 M, MET amp
Ji W et al. [19] 26 10/16 21/5 NA gefitinib T790 M, MET amp, AXL, EMT, CD56
  1. aUncertain for the 3 cases; C or F /N = current or former /never smoker